Year Founded
2018
Ownership
Private
Employees
~50
Stage
Phase 2
Modalities
Small moleculeOther

Gen1E Lifesciences General Information

Company has accelerated from early discovery to Phase 2 in 2.5 years with seed capital. Lead program GEn-1124 is in Phase 2 for ARDS.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office
Palo Alto, California
USA

Drug Pipeline

GEn-1124
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Gen1E Lifesciences's pipeline data

Book a demo

Key Partnerships

University of Maryland, Baltimore, SilcsBio

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Gen1E Lifesciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Gen1E Lifesciences's complete valuation and funding history, request access »

Gen1E Lifesciences Investors

Y Combinator (YC S19)
Investor Type: Venture Capital
Holding: Minority